M. Andrew Wade Net Worth

The estimated Net Worth of M. Andrew Wade is at least $5.28 Million dollars as of 21 February 2020. M Wade owns over 45,000 units of Atricure Inc stock worth over $4,307,228 and over the last 12 years M sold ATRC stock worth over $970,980.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

M Wade ATRC stock SEC Form 4 insiders trading

M has made over 9 trades of the Atricure Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently M exercised 45,000 units of ATRC stock worth $296,100 on 21 February 2020.

The largest trade M's ever made was exercising 45,000 units of Atricure Inc stock on 21 February 2020 worth over $296,100. On average, M trades about 1,988 units every 16 days since 2012. As of 21 February 2020 M still owns at least 160,120 units of Atricure Inc stock.

You can see the complete history of M Wade stock trades at the bottom of the page.

What's M Wade's mailing address?

M's mailing address filed with the SEC is 7555, Innovation Way, Innovation Business Center, Mason, Warren County, Ohio, 45040, United States.

Insiders trading at Atricure Inc

Over the last 19 years, insiders at Atricure Inc have traded over $52,789,242 worth of Atricure Inc stock and bought 666,621 units worth $5,937,195 . The most active insiders traders include Scott William Drake, Group I, Llc Donoghue Danie..., and Management Group Viii L L C.... On average, Atricure Inc executives and independent directors trade stock every 24 days with the average trade being worth of $548,410. The most recent stock trade was executed by Maggie Yuen on 15 August 2024, trading 3,500 units of ATRC stock currently worth $84,245.

What does Atricure Inc do?

atricure, inc. provides innovative technologies for the treatment of afib and related conditions. afib affects more than 33 million people worldwide. electrophysiologists and cardiothoracic surgeons around the globe use atricure technologies for the treatment of afib and reduction of afib related complications. atricure’s isolator® synergy™ ablation system is the first and only medical device to receive fda approval for the treatment of persistent afib. atricure’s atriclip left atrial appendage exclusion system products are the most widely sold laa management devices worldwide, with more than 100,000 implanted to date. for more information, visit atricure.com or follow us on twitter @atricure.

Complete history of M Wade stock trades at Atricure Inc

Atricure Inc executives and stock owners

Atricure Inc executives and other stock owners filed with the SEC include:

• Michael Carrel,
  President, Chief Executive Officer, Director
• Douglas Seith,
  Chief Operating Officer
• Salvatore Privitera,
  Chief Technology Officer
• Justin Noznesky,
  Senior Vice President, Marketing and Business Development
• Scott Drake,
  Independent Chairman of the Board
• Sven Wehrwein,
  Independent Director
• Mark Lanning,
  Independent Director
• B. Kristine Johnson,
  Independent Director
• Robert White,
  Independent Director
• Regina Groves,
  Independent Director
• Mark Collar,
  Independent Director
• Karen Prange,
  Independent Director
• Daniel Florin,
  Independent Director
• Angela Wirick,
  Chief Financial Officer
• Shlomo Nachman,
  Director
• Karen P Robards,
  Director
• Elizabeth D Krell,
  Director
• Richard M Johnston,
  Director
• Michael D Hooven,
  Director
• Andrew L Lux,
  V.P. & Chief Operating Officer
• Group I, Llc Murphy Michael...,
  
• M. Andrew Wade,
  CFO
• Tonya Austin,
  Chief Human Resources Officer
• Deborah L Morley,
  VP Clinical Affairs
• Lee R Wrubel,
  Director
• Maureen Shaffer,
  Vice President Marketing
• Jon A Sherman,
  VP Product Development
• Elsa Chi Abruzzo,
  VP; Regulatory&ClinicalAffairs
• Alan L Kaganov,
  Director
• Richard S Walsh,
  Vice President; Sales
• Management Group Viii L L C...,
  
• Management Group Viii L L C...,
  
• Stephen S Cambridge,
  Vice President; Sales
• Management Group Viii L L C...,
  
• Thomas J Etergino,
  Vice President and CFO
• Norman R Weldon,
  Director
• Patricia J Kennedy,
  VP, GM, International
• James L Lucky,
  VP; QA & Healthcare Compliance
• Management Group Viii L L C...,
  
• David J Drachman,
  President and CEO
• Richard Mcamden Partners St...,
  
• Richard Mcamden Partners St...,
  
• Donald C Harrison,
  Director
• Group I, Llc Donoghue Danie...,
  
• Stewart W Strong,
  Vice President US Sales
• Management Group Viii L L C...,
  
• Frederick Preiss,
  Vice President; Operations
• Julie A Piton,
  VP and CFO
• Deborah H Telman,
  Director
• Karl S. Dahlquist,
  Chief Legal Officer
• Vinayak Doraiswamy,
  Chief Scientific Officer
• Maggie Yuen,
  Director
• Deborah Lee Yount,
  Chief Human Resources Officer